HeyJaredPauline Anderson
- Indexed articles, last 90 days
- 9
- Latest publication
- Sep 29, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 13, 2026
Latest articles
Tenecteplase Before EVT: Is There a Benefit in Late BAO? (opens the original)
Read excerpt
Adding intravenous (IV) tenecteplase before endovascular thrombectomy (EVT) did not improve functional outcomes in patients with basilar artery occlusion (BAO) who presented for treatment 4.5-24 hours after the onset of stroke, new research showed. The multicenter, open-label, randomized controlled trial also revealed that rates of 90-day mortality and symptomatic intracranial hemorrhage weren’t significantly different between those who received thrombolysis and those that didn’t. “Our findings
New Stroke Rehab Guideline Calls for Earlier, Broader Care (opens the original)
Read excerpt
A new American Stroke Association guideline on adult stroke rehabilitation and recovery emphasizes early, individualized rehabilitation and coordinated care from a multidisciplinary team. The first update in a decade recommends beginning rehabilitation as soon as patients are medically stable, ideally within 48 hours of stroke, with ongoing attention to physical, cognitive, communication, and mental health needs. “It’s important to provide rehabilitation for people who have impairments that are
Traffic Noise a Novel Parkinsonâs Risk Factor? (opens the original)
Read excerpt
Long-term exposure to residential traffic noise was associated with a higher risk for Parkinson’s disease (PD), independent of air pollution, green space, and socioeconomic factors, a large Danish study showed. However, this association may be mitigated by having a “quiet façade” that provides residents with a reprieve from excessive noise, researchers noted. “From a prevention perspective, ensuring that dwellings provide a quiet side may be important for reducing the potential neurodegenerative
Lipid-Lowering Med Advances to Alzheimerâs Prevention Trial (opens the original)
Read excerpt
LONDON — A post hoc analysis of a phase 3 trial suggested the lipid-lowering drug obicetrapib may have its greatest effect on the Alzheimer’s disease (AD) biomarker phosphorylated tau 217 (p-tau217) in APOE4 carriers, with new findings that are helping to shape a planned Alzheimer’s prevention trial. Researchers are digging deeper into why APOE4 carriers appear to derive the greatest biomarker benefit from obicetrapib and how those findings can help identify the patients most likely to benefit i
Global Trial to Test Lifestyle Plus Metabolic Tx in Dementia (opens the original)
Read excerpt
LONDON — A global trial will evaluate whether adding a metabolism-targeting therapy to intensive lifestyle intervention can enhance the cognitive benefits of lifestyle changes in older adults at risk for dementia. The Alzheimer's Association has announced the Prevention of Risk fOr cogniTive dEcline through Combined Therapy (PROTECT-Cog) study and will provide $100 million in funding. The study will evaluate a metabolism-targeting therapy, such as a GLP-1 receptor agonist, in combination with li
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.